COMPASS PATHW SP.ADR (F:5Y6) — Market Cap & Net Worth
Market Cap & Net Worth: COMPASS PATHW SP.ADR (5Y6)
COMPASS PATHW SP.ADR (F:5Y6) has a market capitalization of $657.30 Million (€562.22 Million) as of June 16, 2026. Listed on the F stock exchange, this Germany-based company holds position #11070 globally and #1258 in its home market, demonstrating a 56.25% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying COMPASS PATHW SP.ADR's stock price €7.50 by its total outstanding shares 96017044 (96.02 Million). Review COMPASS PATHW SP.ADR (5Y6) total liabilities to assess the company's total debt and financial obligations.
COMPASS PATHW SP.ADR Market Cap History: 2020 to 2026
COMPASS PATHW SP.ADR's market capitalization history from 2020 to 2026. Data shows change from $4.58 Billion to $1.16 Billion (-19.84% CAGR).
COMPASS PATHW SP.ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how COMPASS PATHW SP.ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 5Y6 by Market Capitalization
Companies near COMPASS PATHW SP.ADR in the global market cap rankings as of June 16, 2026.
Key companies related to COMPASS PATHW SP.ADR by market ranking:
- HCA Healthcare, Inc. (NYSE:HCA): Ranked #329 globally with a market cap of $80.16 Billion USD.
- FRESENIUS SE+CO. ADR 1/4 (F:FREA): Ranked #999 globally with a market cap of $26.87 Billion USD ( €22.98 Billion EUR).
- Fresenius SE & Co. KGaA (XETRA:FRE): Ranked #1050 globally with a market cap of $25.58 Billion USD ( €21.88 Billion EUR).
- IHH Healthcare Bhd (KLSE:5225): Ranked #1344 globally with a market cap of $19.28 Billion USD ( RM76.79 Billion MYR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #329 | HCA Healthcare, Inc. | NYSE:HCA | $80.16 Billion | $389.97 |
| #999 | FRESENIUS SE+CO. ADR 1/4 | F:FREA | $26.87 Billion | €10.20 |
| #1050 | Fresenius SE & Co. KGaA | XETRA:FRE | $25.58 Billion | €38.85 |
| #1344 | IHH Healthcare Bhd | KLSE:5225 | $19.28 Billion | RM8.69 |
COMPASS PATHW SP.ADR Historical Marketcap From 2020 to 2026
Between 2020 and today, COMPASS PATHW SP.ADR's market cap moved from $4.58 Billion to $ 1.16 Billion, with a yearly change of -19.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.16 Billion | +83.93% |
| 2025 | €628.62 Million | +48.94% |
| 2024 | €422.08 Million | -53.58% |
| 2023 | €909.26 Million | +4.38% |
| 2022 | €871.09 Million | -58.83% |
| 2021 | €2.12 Billion | -53.80% |
| 2020 | €4.58 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of COMPASS PATHW SP.ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $657.30 Million USD |
| MoneyControl | $657.30 Million USD |
| MarketWatch | $657.30 Million USD |
| marketcap.company | $657.30 Million USD |
| Reuters | $657.30 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About COMPASS PATHW SP.ADR
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as … Read more